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620 The Journal of Thoracic and Cardbjective: Despite the introduction of low potassium–based preservation strategies
or clinical lung transplantation, relevant early graft dysfunction occurs in up to 20%
f cases after lung transplantation. This was found to be frequently associated with
ostreperfusion surfactant dysfunction. We performed a randomized, prospective
tudy investigating the effect of exogenous surfactant instillation into human donor
ungs on posttransplant surfactant function and on clinical outcome.
ethods: Exogenous surfactant was instilled into 15 donor lungs before retrieval via
ronchoscopy. Bronchoalveolar lavage fluids were taken before instillation as well
s 24 hours after transplantation. Surfactant function, phospholipids, and protein
ontent in bronchoalveolar lavage fluids were assessed and clinical data prospec-
ively recorded. Pulmonary function testing was performed 4 weeks after lung
ransplantation. Additionally, the best forced expiratory volume in 1 second was
etermined within the first year after lung transplantation. The control group
onsisted of 14 patients receiving donor lungs without surfactant instillation in
andomized order. Pulmonary function test results were further compared with those
f 154 consecutive recipients of bilateral lung transplants, which were not involved
n the study (historical control).
esults: No deaths occurred during the first year after lung transplantation. Surfac-
ant function in donor lungs was within normal ranges before harvest. In the control
roup, surfactant function was markedly impaired after reperfusion. This was
ignificantly improved by surfactant substitution. Protein content of the bronchoal-
eolar lavage fluid in the surfactant group was significantly lower, indicating less
eakage through the alveolocapillary membrane. Forced expiratory volume in 1
econd after 4 weeks was significantly higher in the surfactant group than in either
ontrol group (P  .034 and .01, respectively). Interestingly, the best forced
xpiratory volume in 1 second during the first year after lung transplantation was
ignificantly higher in both control groups compared with forced expiratory volume
easured in examinations 4 weeks after lung transplantation (P  .01). The best
orced expiratory volumes in 1 second of control patients were comparable with
hose in surfactant lungs 4 weeks after transplant.
onclusions: This study indicates a protective effect of exogenous surfactant instil-
ation to donor lungs before retrieval on post–lung transplantation surfactant func-
ion and on early clinical outcome. This approach may help to improve the outcome
fter lung transplantation in the future.
ne of the major obstacles in clinical lung transplantation is the occurrence
of reperfusion injury, which may lead to life-threatening primary graft
dysfunction. The importance of this issue initiated an enormous effort in
esearch related to experimental lung transplantation. The majority of investigations
ocused on the improvement of pulmonary preservation. With the introduction of
iovascular Surgery ● June 2007
E
a
t
a
s
p
t
p
f
s
l
l
t
t
b
s
w
f
p
t
r
r
b
f
h
e
o
P
I
t
a
e
n
g
(
g
a
m
a
s
p
s
a
p
c
e
b
c
w
d
U
s
r
w
w
D
T
s
d
1
l
t
m
t
G
(
d
R
R
p
N
b
f
c
t
c
A
t
(
w
d
T
H
A
F
T
D
Strüber et al Cardiothoracic Transplantation
TXuro-Collins flush perfusion, a worldwide standard was
nnounced. However, although ischemic times were limited
o 6 hours only, the initial graft function remained unreliable
nd unpredictable. One of the findings was impairment of
urfactant function after reperfusion, a unique feature in
ulmonary preservation and transplantation. In experimen-
al studies, substitution of exogenous surfactant was used to
revent primary graft dysfunction.
We were able to demonstrate a beneficial effect of sur-
actant substitution on graft function in recipients with
evere experimental reperfusion injury.1 A quantum leap in
ung preservation was achieved with the introduction of
ow-potassium dextran (LPD) solution for flush preserva-
ion. A significant improvement of postoperative graft func-
ion was reported in clinical2,3 and experimental studies, and
etter surfactant function was shown.4 The purpose of this
tudy was twofold: The first question addressed was
hether the improvements of surfactant function resulting
rom LPD solution could be verified in clinical lung trans-
lantation. The second aim was to define whether substitu-
ion of exogenous surfactant to the donor at the time of lung
etrieval has an impact on surfactant function beyond the
eperfusion period. The latter question was to be answered
y laboratory assessment of surfactant composition and
unction and not by the early clinical course. Owing to the
igh variability of lung recipients and the high costs of
xogenous surfactant, such a study would have been seri-
usly underpowered and not feasible.
atients and Methods
n a prospective, monocenter, randomized, investigator-initiated
rial, 30 donor lungs for elective double lung transplantation were
ssessed by standard criteria before retrieval. All donors were
valuated consecutively and those with severe neurologic pulmo-
ary edema were excluded from this study. On acceptance of the
raft, randomization was performed and a bronchoalveolar lavage
BAL) was obtained from the right middle lobe. In the control
roup (n  14), lungs were flushed antegradely via the pulmonary
rtery with LPD solution (4-6 L) at 8°C within 10 minutes while
echanical ventilation was continued. Lungs were excised en bloc
nd stored at a mild inflated state in cold (4°C) preservation
olution. In the surfactant group (n  15), a bovine surfactant
reparation (Alveofact; Thomae, Germany) was instilled broncho-
copically (100 mg/kg body weight of the donor) and distributed in
Abbreviations and Acronyms
BAL  bronchoalveolar lavage
BALF  bronchoalveolar lavage fluid
FEV1  forced expiratory volume in 1 second
min minimal surface tension
LPD  low-potassium dextran
SA/LA small-to-large aggregates ratioliquots of 2 to 3 mL to all segments of both lungs. Thereafter, p
The Journal of Thoracicreservation and harvesting were conducted as described for the
ontrol group. One double lung graft was not transplanted and was
xcluded from the study for severe infiltrations found ex situ in
oth lower lobes. Bilateral sequential lung transplantation was
arried out in all recipients via anterolateral minithoracotomies as
e described previously.5 In 12 recipients, the transplant proce-
ure was carried out with the support of cardiopulmonary bypass.
se of cardiopulmonary bypass was statistically comparable in the
urfactant and control groups (P  .91). After transplantation,
ecipients were transferred to the intensive care unit and their lungs
ere mechanically ventilated in a pressure-controlled mode. BAL
as obtained 18 to 24 hours after graft reperfusion.
onor Characteristics
he main causes of deaths in the group of organ donors were
ubarachnoidal bleeding (31%) and head injury (28%). The mean
onor age was 34.6  11.2 years (range, 14-53 years). There were
7 male and 12 female donors, which were mechanically venti-
ated for 77  65 hours (15-240 hours) before multiorgan dona-
ion. The ischemia time ranged from 210 to 640 minutes with a
ean of 392  42 minutes. There was no significant difference in
hese demographics between the surfactant and the control groups.
ender was not statistically different between the surfactant group
8 female donors of 15) compared with the control group (6 female
onors of 14).
ecipient Characteristics
ecipient age, gender, and diagnosis are shown in Table 1. All
atients were candidates for elective pulmonary transplantation.
one was receiving mechanical or noninvasive ventilatory support
efore transplant. Informed consent for the study was obtained
rom each recipient. This trial was approved by the local ethics
ommittee of the Hannover Medical School. Patient insurance for
he trial was supplied.
The immunosuppressive protocol in all study and historical
ontrol patients consisted of a triple drug regimen of cyclosporine
(trough levels 250-350 ng/mL for the first 6 months after lung
ransplantation and 200-300 ng/mL thereafter), mycophenolic acid
2-3 g/day according to body weight), and prednisone (starting
ith 1 mg/kg body weight, followed by a taper regimen to a target
ose of 0.1 mg/kg body weight over 3 weeks). No immunosup-
ABLE 1. Patient characteristics
Recipients
Surfactant Control
eight (cm) 169  7.2 169  9.6
ge (y) 34 11 41  13
emale/male 9/6 8/6
otal lung capacity (L) 5.6 0.9 5.7  0.8
iagnosis
Emphysema 5 4
Cystic fibrosis 5 5
Fibrosis 2 2
Other 3 3ressive induction therapy was administered. Acute rejection was
and Cardiovascular Surgery ● Volume 133, Number 6 1621
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1
TXiagnosed clinically; surveillance biopsy specimens were not
aken. No clinical signs of rejection were found in any patients 10
ays before or after pulmonary function testing.
urfactant Preparation
he bovine surfactant preparation (Alveofact) was supplied by a
enerous donation from Thomae, Germany. The dry preparations
ere dissolved according to the manufacturer’s instructions at the
onor site immediately before bronchoscopic instillation.
urfactant Analysis
ronchoalveolar lavage fluid (BALF) was obtained from the right
iddle lobe in all donors before lung preservation with 100 mL of
ormal saline solution. The lavage was transported with the graft
ooled at 4°C. On arrival at the transplant center, BALFs were
mmediately centrifuged at 150g and the cell-free supernatant was
ept frozen at 80°C until further analysis. A second BAL from
f the left lingula lobe was taken after 18 to 24 hours of graft
eperfusion, centrifuged, prepared, and then kept frozen as above.
Aliquots of the cell-free supernatant were assayed for total
rotein content by standard technique. For surfactant analysis,
AL surfactant lipids were separated into a large surfactant
ggregate–containing pellet and a small surfactant aggregate–
ontaining supernatant by centrifugation of the cell-free BALF at
8,000g for 60 minutes. Phospholipids in the small aggregate–
ontaining supernatant and in the large-aggregate pellet were de-
ermined by phosphorus analysis and their weight expressed as a
mall-to-large aggregate ratio (SA/LA). The surfactant pellet was
esuspended in normal saline supplemented with 1.5 mmol/L cal-
ium chloride to a phospholipid concentration of 1 mg/mL. Sur-
actant function was determined with a pulsating bubble surfac-
ometer (Electronetics, Buffalo, NY) according to the technique
escribed by Enhorning.6 In brief, 40 L of the adjusted large-
ggregate suspension was filled into the sample chamber. The
urface tension at minimal bubble size (min) was obtained after 5
inutes of bubble pulsation at a rate of 20 cycles/min and a
emperature of 37°C. Before bubble pulsation was started, the
nitial surface tension after bubble formation was measured and the
dsorption rate was determined as surface tension 10 seconds after
ormation of a bubble. All analog data were digitalized and re-
orded by a personal computer.
ung Function Analysis
pirometry analysis (forced expiratory volume in 1 second [FEV1]
nd forced vital capacity) was performed 4 weeks after lung
ransplantation. Results in the surfactant group were compared
ith those of controls as well as with 154 consecutive double lung
ransplant recipients outside this study (historic control). In addi-
ion, the best FEV1 was determined within the first year after lung
ransplantation and compared between the two control groups and
he surfactant group.
tatistical Analysis
ata are expressed as mean standard deviation. For data without
epeated measurement, analysis of variance was applied. All data
ere analyzed with the Statistical Program of Social SciencesSPSS for MS Windows Version 12.0; SPSS, Inc, Chicago Ill). p
622 The Journal of Thoracic and Cardiovascular Surgery ● Junesults
ll recipients survived the follow-up period of 1 year. There
as no difference in statistical relevance with respect to
schemic time (second transplanted lung), time of ventila-
ory support after transplantation, and length of stay in the
ntensive care unit or in the hospital between the two
roups. Oxygenation index and lung compliance represent-
ng initial graft function were also comparable. Employing
he arterial oxygenation/fraction of inspired oxygen ratio to
valuate early graft function 6, 12 and 24 hours after lung
ransplantation, these ratios in the nonsurfactant and surfac-
ant populations were 327  87 versus 322  105 (P 
89), 405  142 versus 384  127 (P  .71), and 430 
60 versus 386  104 (P  .42), respectively. Dynamic
ung compliances in nonsurfactant and surfactant patients at
, 12, and 24 hours after lung transplantation were 38  8
ersus 45  6 mL/mm Hg (P  .07), 40  11 versus 44 
1 mL/mm Hg (P  .43), and 42  11 versus 49  12
L/mm Hg (P  .43), respectively.
Diagnosis of acute rejection led to methylprednisolone
ulse therapy (1000 mg/day for 3 days) in 9 patients within
he first 3 months after transplantation. In 5 patients (n  2,
ontrol group; n  3, surfactant group), early treatment
ithin 16 days after transplant was carried out; the remain-
ng patients (2 of each group) received pulse therapy after
he first month.
Surfactant function in the early postoperative period after
ung transplantation was assessed by determination of min-
mal surface tension (min) of BLF in the graft before
arvesting and within 24 hours of transplantation. In all
onor lungs a normal min was found (Figure 1) before lung
igure 1. Minimal surface tension (min) in donor lungs before
etrieval. BALF, Bronchoalveolar lavage fluid.reservation. After transplantation, a significant loss of sur-
e 2007
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TXactant activity with an increase of min was observed.
lthough surfactant function in the control group was mark-
dly impaired (min 17.5  1.9 mN/m), instillation of sur-
actant before lung retrieval prevented the loss of surfactant
unction during the reperfusion period (min 9.6  2.1
N/m; P  .03 compared with control). However, baseline
f min was not reached. Phospholipids were shown to be
omparable before lung preservation and also after trans-
lantation, as depicted in Figure 2. However, the surfactant
nstillation group showed higher phospholipid contents of
he BAL after transplantation. The SA/LA ratio, which was
lready elevated before lung retrieval (all donors, 0.82  0.20;
igure 2. Phospholipids content of bronchoalveolar lavage fluids
BALF).igure 3. Protein content of bronchoalveolar lavage fluids (BALF). S
The Journal of Thoracicontrol group, 0.78  0.31; surfactant group, 0.86  0.24),
as further increased in the control group (1.58  0.44),
ndicating an increased metabolic conversion of surfactant
nto inactive small aggregates. In contrast, surfactant sup-
lementation improved the SA/LA ratio (0.42  0.11; P 
01 compared with control), which indicates improved sur-
actant function.
Compared with measurements in previously reported
ealthy control subjects,7 BALF protein content was found
lightly elevated before lung preservation in donor lungs in
his study. In the control group (Figure 3), protein levels
ignificantly increased from 234  72 mg/L before preser-
ation to 598 141 mg/L after transplantation (P .04). In
rafts that received surfactant instillation, posttransplant
rotein levels (461  141 mg/L) were not significantly
igher than before preservation (286  94 mg/L; P  .21).
etween both recipient groups (Figure 3), the difference of
AL protein content was also statistically significant.
Pulmonary function tests using spirometry 4 weeks after
ransplantation (Figure 4) showed a higher FEV1 in surfac-
ant recipients compared with control patients. FEV1 values
n the control group were comparable with those in a his-
oric control cohort of 154 subsequent lung transplant pa-
ients. In both groups an FEV1 of 62%  8% of the
redicted value was reached. In contrast, the surfactant
ubstitution group revealed a significantly higher FEV1 of
3%  5% (P  .034 and .001, respectively). During the
rst year after transplantation, pulmonary function testing
as compared among all three groups using the best FEV1
s the main value. In the control group of this study, as well
igure 4. Forced expiratory volume in 1 second (FEV1) 4 weeks
fter lung transplantation and best FEV1 in group comparison.
urf, Surfactant.
and Cardiovascular Surgery ● Volume 133, Number 6 1623
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1
TXs in the historical control group, a significant improvement
ompared with the measurement after 4 weeks was found
P  .01) to a best FEV1 of 82%  7%. In the surfactant
ubstitution group, a tendency of further improvement was
oted. However, the best FEV1 of 90%  6% of the
redicted value was not significantly different from 4-week
osttransplant examinations of this group or the best FEV1
n control groups.
iscussion
nitial graft failure after lung transplantation is associated
ith surfactant dysfunction in the graft during the reperfu-
ion period.8 It was established that preservation strategies
sing high potassium-containing solutions (eg, Euro-Collins
olution) contributed to this phenomenon by two mecha-
isms: First, a direct toxic effect of these solutions leading
o an impairment of the integrity and function of alveolar
ype II cells has previously been demonstrated.9 A second
echanism was seen in the increase of permeability of the
lveolocapillary membrane to allow for influx of plasma
roteins into the alveolar space,10 leading to an inhibition of
urfactant function.11 These effects leading to impairment
f graft function could be prevented by substitution of
urfactant preparation before reperfusion of the graft in
uro-Collins–preserved grafts.8 Strategies were investi-
ated when and how to substitute exogenous surfactant.12
owever, with the introduction of LPD solutions in exper-
mental studies, a protection of type II cells, as well as an
mprovement of surfactant function owing to protection of
he integrity of the alveolocapillary membrane, was shown.
To our knowledge, this is the first clinical study inves-
igating surfactant function in the donor lung before lung
ransplantation. There are two potential mechanisms by
hich impairment of surfactant function in donor organs
efore preservation could be induced. One mechanism is the
evelopment of pulmonary edema owing to brain death,
o-called neurogenic pulmonary edema with subsequent
urfactant inactivation by invading plasma proteins. A sec-
nd mechanism could be ventilator-induced lung injury. It
as been demonstrated that mechanical ventilation of nor-
al lungs can induce an impairment of the pulmonary
urfactant system.13 In our study, a normal biophysical
urfactant function, an increased SA/LA ratio, and slightly
levated protein content was found in donor lungs before
reservation. The elevated BALF protein indicates at least
ome leakage of plasma proteins into the alveolar space. It
annot be depicted whether this is more to the result of
echanical ventilation or neurogenic pulmonary edema.
nterestingly, we found an increased SA/LA ratio, which
ight indicate that mechanical ventilation of donor lungs
ffects surfactant conversion. Importantly, we did not find a
ignificant loss of the overall biophysical surfactant func-
ion, which suggests that both brain death and mechanical a
624 The Journal of Thoracic and Cardiovascular Surgery ● Junentilation have little impact on the surfactant activity of
onor lungs.
After lung transplantation, a decrease of surfactant func-
ion was found in the not substituted transplant recipients.
his finding is in contrast to the experimental studies, which
howed proper surfactant activity in the reperfusion period
fter lung transplantation.14 Indeed, the degree of impair-
ent is comparable with that of patients receiving Euro-
ollins–preserved grafts in an earlier study.15 A further
onclusion that can be drawn is that surfactant substitution
o the graft before harvesting can be detected in the BALF
4 hours after transplantation by laboratory means to deter-
ine surface tension, protein content, and phospholipid
evels. We were unable to show any differences in the
ostoperative course of the patients in group comparison.
he impact of surfactant instillation on postoperative lung
unction was not strong enough to be detected in the small
ample size of this study, and it has to be underscored that
his study was not powered to detect such a difference.
nitial graft function and early patient outcome are influ-
nced by many factors, so a much larger cohort of patients
s required to define the impact of surfactant substitution on
he postoperative course. However, there was a strong as-
ociation with lung function testing 4 weeks after transplan-
ation and surfactant instillation. In untreated patients, as
ell as in a larger cohort of transplant recipients with
PD-preserved grafts (historical control), the FEV1 was
nly about 63% of the predicted value, and it took some
eeks to months until the best FEV1 was reached. There-
ore, it is likely that surfactant substitution has an impact on
he recovery of donor lungs after transplantation, as sug-
ested by the observed earlier recovery of FEV1 values. It
an be speculated that surfactant substitution to the donor
ung may indeed have an effect on lung recovery beyond the
nitial postoperative period.
Because preservation of the lung was not satisfactory in
he past, numerous experimental as well as clinical studies
ere carried out to improve initial graft function.14 These
fforts led to the introduction of LPD solution in clinical
ransplantation.2,3 After superior graft function was found
lso in observational clinical studies, LPD received world-
ide acceptance as the new standard of lung preservation.
s a sequel to this development, a remarkable increase of
nternational lung transplant activities was observed, since
ore donor organs seemed to be acceptable and even so-
alled “marginal” grafts were successfully transplanted.
owever, this study indicates that there is still room for
mprovement of pulmonary preservation. It has been re-
orted most recently16 that initial graft failure is still a major
ontributor to perioperative mortality after lung transplan-
ation, with an incidence of about 20%.
Our data show an increase of protein levels in BALF
fter transplantation, indicating the occurrence of a capillary
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Strüber et al Cardiothoracic Transplantationeak and the development of pulmonary edema. Although
his increase is moderate, it must be noted that the grafts
sed in this study were considered “acceptable” but not
marginal,” with absence of significant pulmonary edema
efore preservation. It is speculative, but most likely, that
he inhibition of the surfactant system is aggravated in
o-called “marginal” grafts, which may already have some
egree of capillary leakage before ischemia and reperfusion,
ossibly related to donor brain death and mechanical
entilation.
Further improvements to lung preservation can be
chieved by modifying preservation solutions. We were
ble to show previously that the addition of iloprost,17
lutathione,18 or glycine19 to the flush solution improved
nitial graft function after extended hypothermic ischemia in
pig model of unilateral lung transplantation. Another
pproach is the application of retrograde pulmonary perfu-
ion techniques to achieve a more homogenous protection
f the donor lung.20
In conclusion, this study indicates a protective effect of
urfactant substitution to the lung graft before preservation.
n the past, repeated application of surfactant before pres-
rvation, before implantation, and during reperfusion was
uggested. In our experience, instillation at a singular time
oint seems to be sufficient. It must be noted that implan-
ation of surfactant-treated grafts was technically more de-
anding because deflation of the graft during implantation
oes not occur to the usual extent. The use of surfactant
reparation in clinical lung transplantation was rare in the
ast owing to the high costs. However, the amount of
urfactant preparation used in this study is quite low com-
ared with the use in adult respiratory distress syndrome.21
ost-effectiveness of surfactant substitution should be dis-
ussed at least for “marginal” grafts to further increase the
cceptance rate of those donor lungs. It may also help to
revent initial graft dysfunction after lung transplantation.
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